ChemDiv Inc, a prominent name in the field of drug discovery and drug development solutions, is making significant strides in the establishment of its state-of-the-art biology facility in Cantanhede, Portugal. This cutting-edge lab, located at Biocant Park, is swiftly expanding its capabilities and actively contributing to ChemDiv’s ongoing programs in various areas of research.
Since its inception in 2022, the laboratory has been expanding its capabilities to support ChemDiv’s discovery-stage projects in areas such as oncology, neuroinflammation, and auto-inflammatory diseases. Alongside this, the lab is playing a crucial role in translating robust preclinical research into clinical programs.
As an exciting testament to its expanding portfolio, the biology facility now offers more than 100 established assays and boasts a broad ADMET panel. Moreover, it holds over 40 validated in-vivo models. Leveraging proprietary and partnered hybrid AI solutions, the lab is equipped to provide preclinical and clinical ADME, toxicology, and efficacy modeling. With an international partner network of in-vivo facilities, the lab also offers expertise in a range of innovative formulations and bioanalytical protocols.
ChemDiv’s Biocant staff brings extensive expertise in deploying a variety of discovery platforms and tools. These include protein degraders, molecular glues, macrocyclic compounds, protein-protein inhibitors, peptidomimetics, and antibody conjugates. These solutions are produced in collaboration with ChemDiv’s Bremen hub, known as the ChemDiv-Bremen Strategic Partnership.
CEO Ronald Demuth highlights the significance of the Cantanhede labs for ChemDiv, emphasizing the broader array of capabilities and more flexible project workflows they enable. Demuth also points out that these labs facilitate the expansion of strategic alliances with renowned academic institutions. Biocant Park and the neighboring Coimbra University provide a world-class research environment with strong scientific infrastructure and innovative technologies. The integration of these new resources into ChemDiv’s existing infrastructure ultimately aims to significantly accelerate drug discovery and partnering projects, ultimately benefiting public health in the long run.
Dr. Ruben Karapetian, Head of the Lab, expresses delight in the progress made so far, highlighting the promising results achieved through the combination of ChemDiv’s technology and expertise with the academic rigor of Coimbra graduate programs and the availability of talented individuals.
Looking ahead, the biology facility is set to extend its capabilities to include working with RNA/protein assays and RNA delivery systems. This expansion will further enhance its arsenal of innovative discovery and development solutions.
ChemDiv Inc. has established itself as a global leader in drug discovery and drug development solutions over the past 33 years. Through its commitment to excellence, the company has delivered numerous leads, drug candidates, and novel medicines in various therapeutic areas to esteemed partners around the world.
In conclusion, ChemDiv Inc’s cutting-edge biology facility at Biocant Park in Cantanhede, Portugal, is making significant progress in strengthening its capabilities. With a focus on various areas of research and collaboration with academic institutions, the lab is positioned to drive innovation and accelerate the discovery and development of new treatments.
